A Phase 1/2 Study of Azacitidine, Venetoclax and Pevonedistat in Newly Diagnosed Secondary AML and in MDS or CMMLAfter Failure of Hypomethylating Agents

Authors

Nicholas J Short
Muharrem Muftuoglu
Faustine Ong
Lewis Nasr
Walid Macaron
Guillermo Montalban-Bravo
Yesid Alvarado
Mahesh Basyal
Naval Daver
Courtney D Dinardo
Gautam Borthakur
Nitin Jain
Maro Ohanian
Elias Jabbour
Ghayas C Issa
Wei Qiao
Xuelin Huang
Rashmi Kanagal-Shamanna
Keyur P Patel
Prithviraj Bose
Farhad Ravandi
Ricardo Delumpa
Regina Abramova
Guillermo Garcia-Manero
Michael Andreeff
Jorge Cortes
Hagop Kantarjian

Publication Date

7-8-2023

Journal

Journal of Hematology Oncology

Abstract

BACKGROUND: Pevonedistat is a first-in-class, small molecular inhibitor of NEDD8-activating enzyme that has clinical activity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Preclinical data suggest synergy of pevonedistat with azacitidine and venetoclax.

METHODS: This single-center, phase 1/2 study evaluated the combination of azacitidine, venetoclax and pevonedistat in older adults with newly diagnosed secondary AML or with MDS or chronic myelomonocytic leukemia (CMML) after failure of hypomethylating agents. Patients received azacitidine 75 mg/m

FINDINGS: Forty patients were enrolled (32 with AML and 8 with MDS/CMML). In the AML cohort, the median age was 74 years (range 61-86 years), and 27 patients (84%) had at least one adverse risk cyto-molecular feature, including 15 (47%) with a TP53 mutation or MECOM rearrangement; seventeen patients (53%) had received prior therapy for a preceding myeloid disorder. The CR/CRi rate was 66% (CR 50%; CRi 16%), and the median overall survival (OS) was 8.1 months. In the MDS/CMML cohort, 7 patients (87%) were high or very high risk by the IPSS-R. The overall response rate was 75% (CR 13%; mCR with or without HI 50%; HI 13%). The most common grade 3-4 adverse events were infection in 16 patients (35%), febrile neutropenia in 10 patients (25%) and hypophosphatemia in 9 patients (23%). In an exploratory analysis, early upregulation of NOXA expression was observed, with subsequent decrease in MCL-1 and FLIP, findings consistent with preclinical mechanistic studies of pevonedistat. Upregulation of CD36 was observed, which may have contributed to therapeutic resistance.

CONCLUSIONS: The triplet combination of azacitidine, venetoclax and pevonedistat shows encouraging activity in this very poor-risk population of patients with AML, MDS or CMML. Trial registration ClinicalTrials.gov (NCT03862157).

Keywords

Humans, Aged, Middle Aged, Aged, 80 and over, Azacitidine, Leukemia, Myelomonocytic, Chronic, Treatment Outcome, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Antineoplastic Combined Chemotherapy Protocols

Comments

Supplementary Materials

PMID: 37422688